3 news items
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
DAWN
6 May 24
on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical
Day One's OJEMDA Receives U.S. FDA Accelerated Approval For Relapsed Or Refractory BRAF-Altered Pediatric Low-Grade Glioma
DAWN
23 Apr 24
, or BRAF V600 mutation RAPNO LGG overall response rate (ORR) of 51%Day One receives rare pediatric disease priority
Day One's OJEMDAâ„¢ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
DAWN
23 Apr 24
RAPNO LGG overall response rate (ORR) of 51% Day One receives rare
- Prev
- 1
- Next